NO20074550L - Anvendelse av Lactobacillus Rhamnosus GG for behandling, forebygging eller reduksjon av systemisk inflamasjon hos et spebarn matet med morsmelkerstatning - Google Patents

Anvendelse av Lactobacillus Rhamnosus GG for behandling, forebygging eller reduksjon av systemisk inflamasjon hos et spebarn matet med morsmelkerstatning

Info

Publication number
NO20074550L
NO20074550L NO20074550A NO20074550A NO20074550L NO 20074550 L NO20074550 L NO 20074550L NO 20074550 A NO20074550 A NO 20074550A NO 20074550 A NO20074550 A NO 20074550A NO 20074550 L NO20074550 L NO 20074550L
Authority
NO
Norway
Prior art keywords
prevention
reduction
treatment
breast milk
systemic inflammation
Prior art date
Application number
NO20074550A
Other languages
English (en)
Norwegian (no)
Inventor
Robert J Mcmahon
Josef Neu
Original Assignee
Bristol Myers Squibb Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bristol Myers Squibb Co filed Critical Bristol Myers Squibb Co
Publication of NO20074550L publication Critical patent/NO20074550L/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/74—Bacteria
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/74—Bacteria
    • A61K35/741—Probiotics
    • A61K35/744—Lactic acid bacteria, e.g. enterococci, pediococci, lactococci, streptococci or leuconostocs
    • A61K35/747—Lactobacilli, e.g. L. acidophilus or L. brevis
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/135—Bacteria or derivatives thereof, e.g. probiotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/74—Bacteria
    • A61K35/741—Probiotics
    • A61K35/744—Lactic acid bacteria, e.g. enterococci, pediococci, lactococci, streptococci or leuconostocs
    • A61K35/745—Bifidobacteria
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Mycology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Microbiology (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Nutrition Science (AREA)
  • Food Science & Technology (AREA)
  • Polymers & Plastics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicinal Preparation (AREA)
NO20074550A 2005-04-15 2007-09-10 Anvendelse av Lactobacillus Rhamnosus GG for behandling, forebygging eller reduksjon av systemisk inflamasjon hos et spebarn matet med morsmelkerstatning NO20074550L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US11/106,793 US20060233752A1 (en) 2005-04-15 2005-04-15 Method for treating or preventing systemic inflammation in formula-fed infants
PCT/US2006/010321 WO2006113033A1 (en) 2005-04-15 2006-03-22 Use of lactobacillus rhamnosus gg for the treatment, prevention or reduction of systemic inflammation in a formula-fed infant

Publications (1)

Publication Number Publication Date
NO20074550L true NO20074550L (no) 2007-11-13

Family

ID=36636335

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20074550A NO20074550L (no) 2005-04-15 2007-09-10 Anvendelse av Lactobacillus Rhamnosus GG for behandling, forebygging eller reduksjon av systemisk inflamasjon hos et spebarn matet med morsmelkerstatning

Country Status (11)

Country Link
US (1) US20060233752A1 (pt)
EP (1) EP1871401A1 (pt)
KR (1) KR20070122480A (pt)
CN (1) CN101146544A (pt)
BR (1) BRPI0608328A2 (pt)
CA (1) CA2604842A1 (pt)
MX (1) MX2007012530A (pt)
NO (1) NO20074550L (pt)
RU (1) RU2007137993A (pt)
TW (1) TW200724146A (pt)
WO (1) WO2006113033A1 (pt)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20090258823A1 (en) * 2006-12-08 2009-10-15 George Caroline L S Composition and methods for the prevention and treatment of gastrointestinal infections
MX2009008875A (es) * 2007-02-28 2009-08-28 Mead Johnson Nutrition Co Producto que contiene probiotico inactivado para niños o infantes.
EP1974734A1 (en) † 2007-03-28 2008-10-01 Nestec S.A. Probiotics for reduction of risk of obesity
US8445426B2 (en) 2009-02-02 2013-05-21 Valio Ltd. Peptides and methods for producing them
US20110070334A1 (en) * 2009-09-20 2011-03-24 Nagendra Rangavajla Probiotic Stabilization
US20140093614A1 (en) * 2009-09-20 2014-04-03 Mead Johnson Nutrition Company Probiotic stabilization
US10980269B2 (en) * 2016-12-12 2021-04-20 Mead Johnson Nutrition Company Protein hydrolysates and methods of making same
CN110122877B (zh) * 2018-02-09 2022-12-23 深圳华大基因农业控股有限公司 鼠李糖乳杆菌及其用途
CN108715822B (zh) * 2018-06-13 2021-09-03 吉林省农业科学院 一株鼠李糖乳杆菌及其在制备抗抑郁产品中的应用

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5840318A (en) * 1993-05-11 1998-11-24 Immunom Technologies, Inc. Methods and compositions for modulating immune systems of animals
JPH092959A (ja) * 1995-06-16 1997-01-07 Yakult Honsha Co Ltd ＩｇＥ抗体産生抑制剤および抗アレルギー剤
US6203797B1 (en) * 1998-01-06 2001-03-20 Stephen C. Perry Dietary supplement and method for use as a probiotic, for alleviating the symptons associated with irritable bowel syndrome
US6461607B1 (en) * 1998-08-24 2002-10-08 Ganeden Biotech, Inc. Probiotic, lactic acid-producing bacteria and uses thereof
US6696057B1 (en) * 1999-09-22 2004-02-24 Lacpro Industries, Inc. Composition and method for treatment of gastrointestinal disorders and hyperlipidemia
JP3853673B2 (ja) * 2001-03-09 2006-12-06 森永乳業株式会社 Ｃ型慢性肝炎治療剤

Also Published As

Publication number Publication date
BRPI0608328A2 (pt) 2009-12-29
US20060233752A1 (en) 2006-10-19
KR20070122480A (ko) 2007-12-31
CN101146544A (zh) 2008-03-19
WO2006113033A1 (en) 2006-10-26
CA2604842A1 (en) 2006-10-26
MX2007012530A (es) 2008-02-12
EP1871401A1 (en) 2008-01-02
RU2007137993A (ru) 2009-05-20
TW200724146A (en) 2007-07-01

Similar Documents

Publication Publication Date Title
MY150285A (en) 4-(4-cyano-2-thioaryl)dihydropyrimidinones and their use
EP4393545A3 (en) Novel uses of piperidinyl-indole derivatives
TN2011000466A1 (en) Substituted 2-acetamido -5-aryl-1, 2, 4- triazolones and use thereof
PL1854477T3 (pl) Peptydy hamujące kalikreinę osoczową do zastosowania w leczeniu zaburzeń okulistycznych
TW200637522A (en) Skin treatment articles and methods
PH12013502192A1 (en) Antibodies against human angiopoietin 2
NZ609280A (en) Method for treatment of constipation-predominant irritable bowel syndrome
MX2010009222A (es) Soluciones farmaceuticas, proceso de preparacion y usos terapeuticos.
UA102238C2 (en) 4-(4-cyano-2-thioaryl)dihydro-pyrimidinones and use thereof
MX2010005986A (es) Productos de grano que tienen un edulcorante natural potente y un agente de volumen.
SG166820A1 (en) Use of flibanserin for the treatment of pre-menopausal sexual desire disorders
BRPI0816255A2 (pt) Produto farmacêutico, uso do produto, método para a profilaxia ou o tratamento de doenças, e, composição farmaceuticamente aceitável
MX2010002733A (es) Terapia de intervalo para el tratamiento de tinnitus.
IL216967B (en) The history of 17-hydroxy-17-pentafluoroethyl-astra-9,4 (10)-diene-11-aryl and their use for the treatment of diseases
WO2009071689A3 (de) 5-halogen-substituierte oxindol-derivate und ihre verwendung zur behandlung von vasopressin-abhängigen erkrankungen
MY150931A (en) Substituted oxazolidinones and their use
WO2009114461A3 (en) Angiotensin (1-7) dosage forms and uses thereof
HRP20171742T1 (hr) 2,4,6-trifluor-n-[6-(1-metilpiperidin-4-karbonil)piridin-2-il]benzamid, namijenjen liječenju migrene oralnom ili intravenskom primjenom
MY172984A (en) Use of lactobacillus rhamnosus gg in combination with a long chain polyunsaturated fatty acid for the treatment, prevention or reduction of systemic inflammation in a formula-fed infant
WO2008094054A3 (en) 6, 8-dichlorchroman-3-yl-l, 3-dihydroimidazole-2-thione derivatives and their use for the treatment of cardiovascular disorders
MX349563B (es) Formulacion farmaceutica de fenofibrato nanonizado.
BRPI0608328A2 (pt) uso de lactobacillus rhamnosus gg para tratamento, prevenção ou redução de inflamação sistêmica em um bebê alimentado com fórmula
WO2009001144A3 (en) Pharmaceutical aerosol compositions comprising fluticasone
WO2007116297A3 (en) Use of aminapthone for the preparation of a medicament for treating arteriophaties
WO2011028915A3 (en) Platelet aggregation inhibitors

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application
FC2A Withdrawal, rejection or dismissal of laid open patent application